---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008190"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:55:38.123542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q1 net loss $49M; cash $401.8M; EDIT-301 on track for 20 SCD patients by year-end

## Summary
- Net loss $49.0M ($0.71 per share), vs $50.5M ($0.74) in Q1 2022; collaboration revenue $9.9M up from $6.8M.
- Cash & equivalents $401.8M as of March 31, 2023; expected to fund operations into 2025.
- 19 SCD patients enrolled in EDIT-301 RUBY trial; on track to dose 20 total by year-end; clinical update at EHA June 2023.
- First TDT patient dosed in EDITHAL trial with successful neutrophil and platelet engraftment; data expected by year-end.
- Appointed Emma Reeve as Board Chair and Elliott Levy as independent director; sold iNK programs to Shoreline Biosciences.

## SEC filing metadata
- accession: 0001558370-23-008190
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/0001558370-23-008190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/edit-20230505x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008190
- JSON: https://secwatch.observer/filing/0001558370-23-008190.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008190.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported the first quarter 2023 results: net income net loss attributable to common stockholders was $49.0 million, or $0.71 per share, EPS $0.71 per share.
  - Period: the first quarter 2023
  - Net income: net loss attributable to common stockholders was $49.0 million, or $0.71 per share
  - EPS: $0.71 per share
  - Result: reported results
  source text: Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/0001558370-23-008190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.